Anthera Pharmaceuticals Inc (ANTH) : Hilltop Park Associates scooped up 10,000 additional shares in Anthera Pharmaceuticals Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 8, 2016. The investment management firm now holds a total of 75,000 shares of Anthera Pharmaceuticals Inc which is valued at $225,750.Anthera Pharmaceuticals Inc makes up approximately 3.17% of Hilltop Park Associates’s portfolio.
Other Hedge Funds, Including , Commonwealth Equity Services Inc boosted its stake in ANTH in the latest quarter, The investment management firm added 100 additional shares and now holds a total of 10,895 shares of Anthera Pharmaceuticals Inc which is valued at $34,537.California State Teachers Retirement System reduced its stake in ANTH by selling 3,000 shares or 3.52% in the most recent quarter. The Hedge Fund company now holds 82,243 shares of ANTH which is valued at $258,243.Cutler Group Lp boosted its stake in ANTH in the latest quarter, The investment management firm added 4,300 additional shares and now holds a total of 7,894 shares of Anthera Pharmaceuticals Inc which is valued at $26,919.
Anthera Pharmaceuticals Inc opened for trading at $3.07 and hit $3.19 on the upside on Monday, eventually ending the session at $3.17, with a gain of 3.26% or 0.1 points. The heightened volatility saw the trading volume jump to 4,74,505 shares. Company has a market cap of $131 M.
Many Wall Street Analysts have commented on Anthera Pharmaceuticals Inc. H.C. Wainwright Initiated Anthera Pharmaceuticals Inc on Jul 8, 2016 to “Buy”, Price Target of the shares are set at $10.
Anthera Pharmaceuticals Inc. (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation and autoimmune diseases. The Company’s primary Phase 3 product candidate blisibimod targets elevated levels of Bcell activating factor (BAFF) which has been associated with a variety of Bcell mediated autoimmune diseases including systemic lupus erythematosus or lupus IgA nephropathy lupus nephritis multiple myeloma and others. The Company’s second product candidate Sollpura (liprotamase) is a Phase III investigational pancreatic enzyme replacement therapy (PERT) intended for the treatment of patients with exocrine pancreatic insufficiency (EPI) often seen in patients with cystic fibrosis and other conditions.